青岛海尔生物医疗股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告

Group 1: Share Buyback Overview - The company approved a share buyback plan on January 13, 2025, allowing the repurchase of shares using its own funds through the Shanghai Stock Exchange, with a maximum price of 50 CNY per share and a total fund amount between 100 million CNY and 200 million CNY [1] - The buyback period is set for 12 months from the approval date [1] Group 2: Price Adjustment - Following the annual equity distribution in 2024, the maximum buyback price was adjusted to 49.5367 CNY per share starting June 6, 2025 [2] Group 3: Buyback Progress - As of July 31, 2025, the company had repurchased a total of 1,845,488 shares, representing 0.5804% of the total share capital, with a total expenditure of approximately 59.25 million CNY [3] - The highest and lowest prices for the repurchased shares were 34.69 CNY and 29.86 CNY, respectively [3] Group 4: Compliance and Disclosure - The company will adhere to relevant regulations and will make buyback decisions based on market conditions, ensuring timely disclosure of progress to investors [4]